Rigel Pharmaceuticals (RIGL) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.38% |
| Dec 31, 2025 | -5.13% |
| Sep 30, 2025 | -120.16% |
| Jun 30, 2025 | 23.53% |
| Mar 31, 2025 | -19.95% |
| Dec 31, 2024 | 18.18% |
| Sep 30, 2024 | 38.22% |
| Jun 30, 2024 | 18.57% |
| Mar 31, 2024 | -34.71% |
| Dec 31, 2023 | -23.31% |
| Sep 30, 2023 | 1.10% |
| Jun 30, 2023 | -19.33% |
| Mar 31, 2023 | 53.87% |
| Dec 31, 2022 | -19.49% |
| Sep 30, 2022 | 19.11% |
| Jun 30, 2022 | 18.47% |
| Mar 31, 2022 | -23.79% |
| Dec 31, 2021 | -6.72% |
| Sep 30, 2021 | -123.85% |
| Jun 30, 2021 | 43.41% |
| Mar 31, 2021 | 18.76% |
| Dec 31, 2020 | -26.74% |
| Sep 30, 2020 | -65.91% |
| Jun 30, 2020 | 19.20% |
| Mar 31, 2020 | -3.77% |
| Dec 31, 2019 | -54.97% |
| Sep 30, 2019 | 14.23% |
| Jun 30, 2019 | -40.09% |
| Mar 31, 2019 | 22.84% |
| Dec 31, 2018 | 25.20% |
| Sep 30, 2018 | 9.25% |
| Jun 30, 2018 | 31.30% |
| Mar 31, 2018 | 22.14% |
| Dec 31, 2017 | 13.18% |
| Sep 30, 2017 | -65.26% |
| Jun 30, 2017 | -30.84% |
| Mar 31, 2017 | 45.94% |
| Dec 31, 2016 | -179.23% |
| Sep 30, 2016 | 15.34% |
| Jun 30, 2016 | -9.14% |
| Mar 31, 2016 | -30.15% |
| Dec 31, 2015 | 18.84% |
| Sep 30, 2015 | 32.56% |